Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors
March 09, 2022 01:30 ET
|
OSE Immunotherapeutics
At American Association for Cancer Research Annual Meeting 2022New Orleans, April 8 – 13 NANTES, France, March 09, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE),...
OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors
February 18, 2022 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, Feb. 18, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the appointment by cooptation of Alexandre Lebeaut as an independent...
OSE Immunotherapeutics is Pleased to Announce that Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, has Obtained FDA Fast-Track Designation for CD28 Antagonist VEL-101/FR104
February 17, 2022 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, Feb. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, has obtained...
Transfer of OSE Immunotherapeutics’ Shares from Compartment C to Compartment B of Euronext Paris from January 31, 2022
February 01, 2022 01:30 ET
|
OSE Immunotherapeutics
NANTES, France, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that its shares have been transferred from compartment C to compartment B...
OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104
January 31, 2022 12:00 ET
|
OSE Immunotherapeutics
Based on the global license agreement signed in April 2021, this first milestone triggers a €5 million payment from Veloxis Pharmaceuticals, Inc. to OSE Immunotherapeutics. NANTES, France, Jan. ...
OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients
January 25, 2022 12:30 ET
|
OSE Immunotherapeutics
Issued by the Japanese Patent OfficeA New Protection Covering Tedopi® Until 2037 NANTES, France, Jan. 25, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)...
OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles
January 17, 2022 01:30 ET
|
OSE Immunotherapeutics
NANTES, France, Jan. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the departure of Alexis Peyroles as Chief Executive Officer. Dominique...
OSE Immunotherapeutics Strengthens Leadership Team with the Appointment of Laurence de Schoulepnikoff as Chief Business Officer
December 21, 2021 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, Dec. 21, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the appointment of Laurence de Schoulepnikoff as Chief Business Officer (CBO),...
OSE Immunotherapeutics is Pleased to Announce the Continuation of its Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis after the Interim Futility Analysis
December 13, 2021 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, Dec. 13, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces today that the trial’s Independent Data Monitoring Committee (IDMC) completed...
OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia
December 13, 2021 01:30 ET
|
OSE Immunotherapeutics
NANTES, France, Dec. 13, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first preclinical data on anti-leukemic efficacy of anti-IL-7 receptor...